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Internephron heterogeneity of growth factors and sclerosis—Modula-
tion of platelet-derived growth factor by angiotension II. We studied the
early phase after 5/6 nephrectomy in Munich-Wistar rats to determine
whether treatment with angiotensin II receptor antagonist (AuRA)
modulates the expression of platelet-derived growth factor (PDGF)
mRNA and its protein among the glomeruli which are undergoing
progressive hypertrophy and sclerosis. Average PDGF-B immunohisto-
chemistry staining score (IHS, 0 to 3 scale) in glomeruli and PDGF-B
chain mRNA from kidneys were both increased in 5/6 nephrectomy rats
(N = 6) versus age-matched normal (N = 5) at week 4, when glomeruli
were at early stages of sclerosis (IHS, 0.81 0.12vs. 0.19 0.05; sclerosis
index, SI., 0 to 4 scale: 0.41 0.04 vs. 0.05 0.01, both P < 0.05). AuRA
(80 mg/liter drinking water, N = 6) started at time of 5/6 nephrectomy
prevented the development of sclerosis (S.I. 0.08 0.03) and decreased
PDGF-B protein (IHS 0.22 0.08, both P = NSvs. normal), and PDGF-B
chain mRNA. In contrast, triple therapy (TRX; hydralazine, reserpine and
hydrochiorothiazide, N = 5) in doses which controlled systemic blood
pressure resulted in intermediate level of glomeruloscierosis at this early
time point of progressive injury. Concurrently, TRX failed to affect the
expression of PDGF-B protein (IHS 0.86 0.19) or its mRNA expression.
The PDGF-B distribution was not uniform amongst the glomeruli with
varying stages of sclerosis. There was a strong correlation in individual
glomeruli of increased PDGF-B staining with early sclerotic changes (P <
0.01), with the disappearance of this correlation in glomeruli with ad-
vanced sclerosis. These results indicate that the structure-preserving effect
of angiotensin H antagonism involves attenuation of the increased expres-
sion of PDGF-B protein and its mRNA, which precede advancement of
glomeruloscierosis. Since angiotensin II inhibition in this model has been
previously shown by us to be therapeutically effective only on glomeruli
with early stage sclerosis, glomerular PDGF expression within affected
kidneys may predict not only the risk for progression, but also potential
therapeutic efficacy of angiotensin II inhibition.
Inhibition of angiotensin II (Ang II) is effective in attenuating
the progressive deterioration of glomerulosclerosis in animal
models [1.-li]. Ang II is not only a potent contractile agonist, but
also can act as a growth factor in vascular smooth muscle cells and
mesangial cells [5, 12—14], where it may do so by inducing other
growth factors. Thus, Ang II activates immediate early genes,
including c-fos, c-myc, followed by increases in the growth factors
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PDGF and TGF-f3 in vascular smooth muscle cells [15—21]. It is
conceivable, therefore, that the sequential activation and poten-
tial interaction of proto-oncogenes and growth factors may be an
important mechanism in angiotensin-induced mesangial cell
growth and matrix production, ultimately leading to glomerulo-
sclerosis. Platelet-derived growth factor (PDGF), derived poten-
tially from platelets, macrophages, smooth muscle cells and
mesangial cells [22, 23], can act as a growth factor for mesangial
cells. Both PDGF and PDGF receptor are induced in several
animal models of renal disease, including the remnant kidney
[23—26]. Moreover, neutralizing polyclonal antibody to PDGF
inhibited mesangial cell proliferation and prevented the increase
of deposition of extracellular matrix associated with anti-Thy-i
glomerulonephritis [27]. These results indicate that PDGF may be
one of the key growth factors involved in the structural derange-
ment taking place within the glomerulus in the early phase of
progressive renal disease.
Of note, chronic renal injury does not involve glomeruli in a
uniform pattern. Glomeruli are not only highly heterogeneous in
their structural damage, but also in their responsiveness to
therapy. Previously, we have shown that whereas early sclerosis in
the remnant model responds to inhibition of Ang II by angioten-
sin converting enzyme inhibitor (ACEI) or angiotensin II receptor
antagonist (AuRA), glomeruli with more advanced lesions at the
time of intervention were not affected, and showed ongoing
progressive injury [1]. It appears that glomeruli, depending on the
stage of sclerosis, are under the influences of quantitatively and/or
qualitatively varying degrees of pathogenic growth factors. We
investigated in the current study whether the therapeutic effect of
Ang II inhibition involves attenuation of such potentially patho-
genic growth factor activities, and if so, whether the inhibitory
effect of Ang II on the growth factor, specifically PDGF, can
determine the efficacy of Ang II on the deteriorating glomerulus.
Methods
Experimental design
Experiments were performed in adult male Munich-Wistar rats
weighing 188 to 267 grams. Rats underwent subtotal nephrectomy
(sNx), that is, right nephrectomy and ligation of two or three main
branches of the left renal artery by silk ligature to leave approx-
imately 1/6 to 1/8 of total kidney tissue mass. The surgery was
131
132 Tanaka et al: Modulation of PDGF by Ang II
performed under anesthesia with sodium pentobarbital (Nembu-
tal, 30 mg/kg body wt, i.p.). The sNX rats were then divided into
three groups. No treatment group (N = 12) received no antihy-
pertensive therapy. AuRA group (N = 11) received L-158,809,
[80 mg/liter drinking water (DW); Merck Research Laboratories,
Rahway, NJ, USA], an angiotensin II receptor antagonist which
shows high affinity and selectivity for the type 1 receptor with no
agonist activity. The drug is orally active with long-lasting effects,
over six hours after a single dose in the rat [28—30] and has the
same receptor specificity as lostartan (Merck), a newly developed
drug now in clinical trials. This dose is fourfold higher than the
minimum antihypertensive dose [5]. TRX group (N = 5) received
so-called triple therapy (TRX; a combination of reserpine 5
mg/liter DW, hydralazine 80 mg/liter DW and hydrochlorothia-
zide 25 mg/liter DW). This dose, although normalizing systemic
blood pressure in previous studies in this model, does not protect
against glomeruloscierosis in long-term studies [3, 5]. The animals
were allowed free access to regular rat chow before and after sNx.
No treatment rats were sacrificed and renal tissue was obtained at
weeks 1 (N = 6) and 4 (N = 6) following sNx. AuRA rats were
sacrificed at week 1 (N =5) and week 4 (N = 6). TRX rats (N =
5) were sacrificed at week 4. Systemic blood pressure was mea-
sured before sacrifice by tail cuff method [31]. In TRX group,
systemic blood pressure was also measured at week 1. Kidneys
harvested from normal age-matched rats (N = 5) that did not
undergo experimental manipulation were used as control for
morphologic studies, immunohistochemistry and Northern analy-
Histological study
Tissue from each rat was fixed in methyl Carnoy's solution
(60% methanol, 30% chloroform and 10% acetic acid), routinely
processed, paraffin embedded and 4 .tm sections cut and stained
with periodic acid Schiff. Histological examination was performed
without knowledge of the treatment protocol. A semiquantitative
score (sclerosis index) was used to evaluate the degree of glomer-
ular sclerosis using the modified method of Raij, Azar and Keane
[32]. Sclerosis was defined as collapse and/or obliteration of the
glomerular capillary tuft accompanied by hyalin material, increase
of matrix and/or adhesion of the tuft to Bowman's capsule. On a
single section of the kidney, glomerulosclerosis was assessed by
examining all glomeruli and severity of sclerosis for each glomer-
ulus was graded from 0 to 4+. Thus a 1+ lesion represented
sclerosis of up to 25% of the glomerulus, while 4+ represented
sclerosis of 75 to 100% of the glomerulus. A whole kidney
sclerosis index (S.I.) was obtained by averaging scores from all
glomeruli of one section.
Tissue was also stained for PDGF B-chain protein using the
murine monoclonal antibody PGF-007 (Mochida Pharmaceutical,
Tokyo, Japan) [26, 27]. PDGF antibody PGF-007 was generated
to a 25 amino acid peptide located near the COOH-terminus of
the PDGF B-chain (residues 73 to 97 of the mature B chain of
PDGF). Immunoblots and SDS-PAGE studies showed that PGF-
007 recognized PDGF-AB and PDGF-BB, but not PDGF-AA.
PGF-007 did not cross-react with human epidermal growth factor,
fibroblast growth factor or platelet factor 4 [33]. The specificity of
PGF-007 was also demonstrated in studies of fixed tissues [34].
The sections were incubated in 0.3% hydrogen peroxide in
methanol for 30 minutes to block endogenous peroxidase activity
and to permeabilize the cells. Nonspecific binding of mouse IgG
Table 1. Systemic parameters
Blood pressure
mm HgBody (Kidney weight/
weight g body weight) x 100 1 week 4 weeks
166±7c 179±7c
112±6 113±3
124±3 106±6
No treatment 257 8 0.52 0.02
AuRA 226 7 0.42 0.02
TRX 219 6b 0.47 0.02
Body and kidney weights are from animals sacrificed at 4 weeks. In the
no treatment and AuRA groups, rats were sacrificed after systemic blood
pressure measurement at 1 or 4 weeks. Abbreviations are: AuRA,
angiotensin receptor antagonist; TRX, triple therapy.
a P < 0.05 and bP < 0.01 vs. No treatment
P < 0.01 vs. normal rats (116 4mm Hg)
was blocked by pre-incubation with normal horse IgG. The
sections were sequentially incubated at room temperature with
murine monoclonal antibody PGF-007 (1.25 g/ml) for two hours,
biotinylated anti-mouse IgG for 30 minutes, and avidin-peroxi-
dase (Vectastain elite ABC kit; Vector Laboratories, Burlingame,
CA, USA) for an additional 30 minutes. Each incubation was
followed by a wash in PBS. Staining was visualized with 0.05%
diaminobenzidine tetrahydrochloride/0.01% hydrogen peroxide
in 0.1 M Tris buffer, pH 7.2. Negative controls with normal mouse
serum instead of the specific antiserum at the same protein
concentration showed no staining. PDGF-B protein was quanti-
tated by immunostaining in individual glomeruli using the follow-
ing semiquantitative scale [26]:
grade 0 - glomerular cells and mesangial matrix negative
grade 1 - weak staining of 1 or 2 cells and/or <25% of the
mesangium weakly positive
grade 2 - intense staining of 1 or 2 cells and/or weak staining of
3 or more cells and 25 to 50% of the mesangium positive
grade 3 - intense cytoplasmic staining of 3 or more cells and/or
>50% of the mesangium positive.
All glomeruli were scored and the percentage of glomeruli from
each kidney in each grade calculated. A minimum of 60 glomeruli
was analyzed for each kidney specimen. On serially sectioned
specimens, the degree of glomerulosclerosis and immunostaining
of PDGF-B were compared in >35 glomeruli in each of four sNx
rats (total 253 glomeruli), and in each of three normal rats (total
200 glomeruli).
RNA isolation and Northern analysis
Total RNA of whole kidney was prepared by acid guanidinium
thiocyanate extraction as described previously [35]. Kidney
mRNA samples for each group at each time point were pooled,
and 20 j.tg of total RNA of each sample was quantified by UV
spectrophotometry and separated through 1% agarose/2.2 M
formaldehyde gel electrophoresis. Northern blotting was per-
formed by capillary transfer in 20 X standard saline citrate (SSC:
1 x SSC is 0.15 M NaCl, 0.015 NI sodium citrate, pH 7) to nylon
membrane (GeneScreen, Nen Research Products, Wilmington,
DE, USA). The membranes were briefly rinsed in 5 X SSC and
nucleic acid cross linking was performed by ultraviolet irradiation
for six minutes on a transilluminator. The blots were then baked
at 80°C for one hour and hybridization was performed using the
following modification of a published procedure [36]. Prehybrid-
ization was carried out for two hours at 65°C in prehybridization
sis.
PDGF-B
PDGF-A
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buffer containing 5x standard saline citrate phosphate (1 X SSCP
is 0.12 M NaC1, 0.015 M sodium citrate and 0.021 M sodium
phosphate), lx Denhardt's, 1% sodium dodecyl sulfate (SDS)
and 100 g/ml denatured salmon sperm DNA. Hybridization was
performed for 20 hours at 65°C in hybridization buffer containing
4 x SSCP, lx Denhardt's, 1% SDS, 100 g/ml denatured salmon
sperm DNA and 10% dextran sulfate, using eDNA probes labeled
by random primer (Random primed DNA labeling kit; Boehr-
inger Mannheim Biochemica, Indianapolis, IN, USA). After
hybridization, membranes were washed two times for 30 minutes
at 65°C with 0.1% SDS/l x SSCP for PDGF-A chain and
PDGF-B chain, 0.1% SDS/1 X SSCP, 0.1 X SSCP, for beta-actin.
Blots were then exposed to x-ray films (Kodak X-Omat) for six
hours to three days at —80°C.
The following probes were used: (a) a 906 base pair of the
mouse PDGF-A chain gene; (b) a 750 base pair of the mouse
PDGF-B chain gene; and (c) to validate the differences in hybridiza-
tion signal intensities, a 704 base pair rat beta-actin cDNA probe
was used as a control. Both PDGF probes contain full length
coding sequences. A description of the PDGF-A clone has been
—3.5kb
—1.7kb
Fig. 1. Northern blot of PDGF-B and PDGF-A
mRNA from kidneys of normal rats, sNX rats and
sNx rats treated with AuRA or TRX at 1 or 4
weeks. 13-actin was used as an internal control.
Abbreviations are: sNx, subtotal nephrectomy;
AuRA, angiotensin II receptor antagonist;
TRX, triple therapy; reserpine,
hydrochlorothiazide and hydralazine; CONT:
normal rats; No Rx: sNx without further
treatment.
published [37]. The probe for PDGF-B chain was derived from
placentas of the C57 black mouse by polymerase chain reaction
(performed by Dr. Susan Jones in Dr. Stiles' laboratory, Dana-
Farber Cancer Institute, Boston, MA, USA). Cos cells transfected
with this PDGF-B chain probe can synthesize biologically active
PDGF-B chain (Dr. C.D. Stiles, personal communication). To
quantit' the relative amounts of mRNA, the film was scanned at
550 nm using a dual wave length TLC scanner (CS930, Shimada,
Kyoto, Japan), and the area corresponding to each transcript was
computed. Optical density ratio in arbitrary units of PDGF-B or
-A chain mRNA relative to beta-actin was then calculated.
In situ hybridization
Tissues from normal (N =2) and sNx (N = 2) rats at four weeks
were fixed overnight in 4% paraformaldehyde at 4°C, processed
routinely, embedded in paraffin and stored at 4°C until hybridiza-
tion studies. Four micrometer sections were then cut and placed
on polylysine (Sigma, St. Louis, MO, USA) treated glass slides
[38]. Slides were dewaxed in xylene, then hydrated serially in
100-30% ethanol. Slides were refixed in 4% paraformaldehyde for
-actin —2.2kb
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Fig. 2. In situ hybridization with antisense PDGF-B mRNA of normal (a) and untreated sNX (b) rat kidney at 4 weeks (X430). Low level glomerular signal
is present in normal rats. Both tubular and intraglomerular signals appear increased in rats after subtotal nephrectomy.
Fig. 3. Glomerular moiphology and immunohistochemical staining for
PDGF-B protein in serial sections of the same glomeruli. Glomeruli from
normal rats typically had no mesangial expansion or glomeruloscierosis
(A) and were negative for PDGF-B protein (B, serial section of the same
glomerulus as A). By 4 weeks after subtotal nephrectomy, glomeruli from
untreated rats were enlarged and some showed mesangial expansion (C)
and a significant increase in intraglomerular cells positive for PDGF-B
protein (D, same glomeruli as C). Of note, the glomerulus in the left
corner without mesangial expansion does not show significant PDGF-B
chain staining. A glomerulus with a segmental sclerotic lesion (sclerosis
index <1; E) shows most intense PDGF-B chain staining on the rim of the
sclerosis (F, same glomerulus as E). In the rare glomeruli with more
advanced sclerosis (G), PDGF staining was not present in the sclerotic,
hyalinized lesion, but rather showed strong staining of the remaining tuft,
as yet not sclerosed (H). In contrast, glomeruli from the AuRA group
were negative for PDGF-B protein (I). (A-I, X430, periodic acid Schiff or
PDGF-B chain immunostaining.) The reproduction of this figure in color
is made possible by a grant from Merck Research Laboratories, Rahway,
New Jersey.
20 minutes, PBS washed and then treated with 20 g/ml protein-
ase K in 50 mrvi Tris-HC1, pH 7.4 and 5 mM EDTA for 7.5 minutes
[391. Subsequently slides were treated with 0.1 M triethanolamine
for 10 minutes, followed by addition of 0.4% (vol/vol) acetic
anhydride for 10 minutes. After rinsing in PBS, slides were
successively dehydrated in 30%-100% ethanol. Two X 106 cpm/
slide of 35S-labeled cRNA for PDGF-B chain and control 35S-
labeled probes were used. Hybridization buffer contained 50%
deionized formamide, 10% dextransulfate, 8 mivi DTT, 0.2 mg/mI
tRNA and lx Salts (300 mrvi NaCI, 10 mM Tris-HCI, 5 mMEDTA,
0.02% polyvinylpyrolidone, 0.02% Ficoll and 0.02% BSA). Slides
were incubated overnight at 50°C in a sealed humidified container
(lx Salts and 50% formamide). Subsequently slides were washed
in 50% formamide, 2 X SSC (300 mrvt NaC1, 30 mM sodium citrate,
pH 7.0), 20 mrvi DIT at 50°C for 60 minutes, followed by TEN
buffer (10 mrvt Tris-HC1, pH 7.6, 5 mrvi EDTA and 500 msi NaC1)
at 37°C, and then treated with 50 .tg/ml RNase at 37°C for 30
minutes [40]. Slides were washed in 2 x SSC, followed by 0.1 X
SSC at 50°C, dehydrated in 30%-100% ethanol with 0.3 M
ammonium acetate and air dried. They were dipped into photo-
graphic emulsion (Polysciences Inc., Warrington, PA, USA),
diluted 1:1 in 2% glycerol solution, then dried overnight in a box
and exposed at 4°C for one week. The slides were developed with
D-19 developer and counterstained with 0.05% toluidine blue. We
used a 750 bp fragment from eDNA of mouse PDGF-B which was
located within the protein coding region. After linearization of the
plasmid containing PDGF-B by pertinent restriction enzymes, we
transcribed sense and antisense cRNA of PDGF-B using RNA
polymerases with labeled 35S-UTP (Du Pont, Boston, MA, USA).
Sense cRNA was used as a negative control.
Statistical method
Results are expressed as mean standard error (SE). Nonpara-
metric data from multiple groups were tested using the Kruskall-
Wallis test followed by Mann-Whitney U test with modification by
Bonferroni's method. Parametric data from multiple groups were
compared using one-way analysis of variance (ANOVA) followed
by t-test with modification by Bonferroni's method. Relationship
between sclerosis index and PDGF staining scores in individual
glomeruli was analyzed by chi-square test for goodness of fit.
Results
Body weight, kidney weight and systemic blood pressure
Body weights were comparable between groups at the start of
experiments. As shown in Table 1, body weights of rats treated
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Table 2. Glomerular SI. and PDGF-B staining scores
SI. PDGF-B staining score
1 week 4 weeks 1 week 4 weeks
No treatment
AuRA
TRX
Normal rats
0.10 0.04
0.07 0.02
0.05
0.41 0.04a
0.08 003b
0.14 003a,b
0.01
0.35 0.08 0.81 0.12
0.18 0.02 0.22 008b
0.86 o.19
0.19 0.05
Abbreviations are: SI., sclerosis index; PDGF-B, platelet-derived
growth factor-B chain; AuRA, angiotensin II receptor antagonist; TRX,
triple therapy.aP < 0.05 vs. normal rats
bP < 0.05 vs. No treatment
with AuRA or TRX at four weeks after subtotal nephrectomy
were significantly lower than those of rats with no treatment (P <
0.05 and P < 0.01, respectively). Kidney weight normalized for
body weight in AuRA, but not TRX, was significantly lower than
that in untreated rats (P < 0.05). High systemic blood pressure
was already noted in untreated rats at one week after subtotal
nephrectomy and continued throughout the four week period.
Treatment with AuRA or TRX markedly and similarly attenu-
ated blood pressure to normal levels.
PDGF-A and PDGF-B chain gene expression
Figure 1 shows the expression of PDGF-B chain (3.5 kb) and
PDGF-A chain (1.7, 2.3 and 2.8 kb) analyzed by Northern blot
analyses. Densitometric analysis of the Northern blots for
PDGF-B chain mRNA showed untreated was 163% of control
(and 185% of AuRA) at one week and 167% of control at four
weeks, TRX 142% of control at four weeks, and AuRA 88% of
control at one week and 104% of control at four weeks (arbitrary
O.D. units, expressed as comparison of ratios to beta actin). Thus,
the mRNA levels of PDGF-B chain in no treatment rats at one
week and four weeks after nephrectomy were higher than those
observed in normal rats. In contrast, the mRNA of PDGF-B chain
in AuRA-treated rats at one week and four weeks after nephrec-
tomy did not increase. In contrast, the mRNA levels of PDGF-B
chain in TRX-treated rats increased markedly compared with
AuRA-treated rats and normal rats. mRNA levels of PDGF-A
chain showed no difference among groups. Beta-actin expression
was unchanged throughout the experiments.
Localization of PDGF-B mRJ'JA in the kidney by in situ
hybridization
The localization of expression of PDGF-B mRNA was exam-
ined by the in situ hybridization method (Fig. 2 a,b). Intraglo-
merular cells in normal rats expressed PDGF-B chain mRNA
weakly in virtually all glomeruli. Although specific cell types could
not be identified with certainty, signal appeared to be present in
some visceral epithelial cells and also mesangial regions. In
contrast, intraglomerular and tubular localization of PDGF-B
chain in remnant kidney appeared markedly increased. Glomer-
ular signal was consistent with mesangial area and possible
visceral epithelial cell production. Tissue examined with a sense
cRNA probe for the PDGF-B chain mRNA showed no localiza-
tion of specific signal. These results confirm that intraglomerular
cells, likely mesangial, visceral epithelial and/or infiltrating cells,
produce PDGF-B protein.
Table 3. Relationship between SI. and glomerular PDGF-B staining
scores
Glomerular
PDGF-B staining scores
Grade Grade Grade Grade
distribution 0 I II III
Glomeruli in
normal rats
89% 8% 3% 0% p < 0.01
Intact glomeruli 61% 27% 10% 2%
in no treatment P < 0.01
Glomeruli with 28% 26% 32% 19%
ME. or S.I. =
1 in no
treatment
Abbreviations are: S.I., sclerosis index; PDGF-B, platelet-derived
growth factor-B chain; M.E., mesangial expansion. Most glomeruli in
normal rats showed no staining or only weak positivity. However, even
intact glomeruli in 5/6 nephrectomy rats showed increased staining score
for PDGF-B.
Histochemical studies
Table 2 shows the degrees of glomerular sclerosis and immu-
nohistochemical staining for PDGF-B protein in untreated sNx
rats (no treatment), AuRA-treated rats, TRX-treated rats and
normal rats. The degrees of sclerosis at one week after sNx in no
treatment rats and AuRA-treated rats were not different from
normal rats. However, the degree of sclerosis four weeks after
subtotal nephrectomy increased significantly in no treatment rats
compared with normal rats (P < 0.05). AuRA treatment pre-
vented the development of sclerosis compared to no treatment
(P < 0.05). Thus, glomerulosclerosis was not different from that
seen in normal rats (P = NS). In contrast, the degree of sclerosis
in TRX-treated rats was intermediate at this early time point of
progressive glomerulosclerosis. Sclerosis increased significantly
compared with normal rats (P < 0.05), but was significantly lower
than that of no treatment (P < 0.05).
Immunohistochemical staining for PDGF-B protein in normal
Munich-Wistar rats was distributed mainly throughout tubular
epithelial cells of cortex and medulla. The basolateral side was
stained more strongly than apical side. The ascending thick limb
in outer medulla also showed strong positive staining. However,
normal glomeruli had only rare and weakly positive cells for
PDGF-B protein. The immunohistochemical staining distribution
in sNx rats at one week after nephrectomy was not different from
normal rats (Fig. 3 a,b). By four weeks after nephrectomy the
staining pattern changed: positive cells were localized to the
mesangial area and positivity was also noted in the cytoplasm of
visceral epithelial cells (Fig. 3 c-h). Average glomerular staining
score at week 4 in no treatment and at week 4 in TRX-treated rats
increased significantly compared to normal rats (P < 0.05).
Furthermore, in these rats, some proximal tubules showed in-
creased staining, equal in intensity to the ascending thick limb in
outer medulla in both groups. In contrast, AuRA-treated rats
showed similar localization of PDGF-B protein staining as normal
rats throughout the experiments (Fig. 3 i). Table 3 shows the
relationship between S.I. and glomerular staining score at week 4
in the individual heterogeneously affected glomeruli in no treat-
ment and normal rats. Most normal rat glomeruli showed no
staining or were only weakly positive. However, in untreated sNx
rats, even glomeruli that appeared intact by light microscopy
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showed significant increase in PDGF-B staining compared to
intact glomeruli in normal rats (P < 0.01) (Fig. 3 c,d). Glomeruli
with only mesangial expansion/hyalinosis or grade 1 S.I.(Fig. 3
e,f), showed further increased PDGF-B staining compared to the
intact glomeruli in these sNx rats (P < 0.01). Thus, the degree of
glomerulosclerosis among these heterogeneous glomeruli with
early sclerosis had a strong positive correlation with increased
PDGF-B staining in these same glomeruli. This colocalization of
early, but not late, sclerosis and PDGF-B staining was also evident
within individual glomeruli with segmental sclerosis. Thus, in
glomeruli with advanced sclerotic lesions (S.I. > 2), the sclerotic
loops showed only weakly positive staining for PDGF-B, whereas
adjacent nonsclerotic capillary loops showed strong PDGF-B
staining, and distant uninvolved loops in the same glomerulus did
not stain (Fig. 3 g,h).
Discussion
Expressions of PDGF-B chain mRNA and B protein were
increased at four weeks in the remnant kidney. In situ hybridiza-
tion studies confirmed production of PDGF within the glomerulus
[41]. Of interest, proximal tubular cells, which have abundant Ang
II receptors, showed increased PDGF protein staining in 5/6
nephrectomy rats and AuRA decreased this expression. As
PDGF produced by the medullary collecting duct was shown to be
mitogenic for renal medullary fibroblasts [42, 43], it is conceivable
that interstitial fibrosis, which is commonly associated with gb-
merulosclerosis, may be in part due to activation of tubular
PDGF, and that Ang II may modulate this activity.
Both glomerulosclerosis and PDGF expressions were decreased
by treatment with AuRA, but not with nonspecific antihyperten-
sive treatment (TRX) with similarly successful systemic blood
pressure control. The results therefore suggest that Ang II
specifically is involved in the enhanced PDGF expression in the
remnant kidney and that this interaction is unique to early
glomerulosclerosis. Our previous studies have found a tight
correlation of glomerular hypertrophy and glomerulosclerosis
among individual glomeruli [2]. The present immunohistochemi-
cal studies compared, within the same gbomeruli, sclerosis index
and expression of PDGF-B, a growth factor known to promote
mesangial cell growth and matrix production. Despite the marked
heterogeneity in both these parameters throughout the renal
cortex, a strong correlation was detected between PDGF expres-
sion and early development of glomerulosclerosis at the individual
glomerular level. In contrast to absence of staining in glomeruli of
normal animals, some intact glomeruli in 5/6 nephrectomy rats
showed strong positive staining of PDGF-B. Those glomeruli may
be at a pre-histological, incipient stage of sclerosis or at "high
risk" for glomerulosclerosis. Such glomeruli also have greatest
potential benefit from therapeutic intervention. In contrast, gb-
meruli with more advanced sclerosis did not have augmented local
PDGF, and our previous studies have shown that this stage of
sclerosis is not responsive to effects of renin-angiotensin system
inhibitors [1]. Furthermore, TRX therapy only partially prevented
the development of glomerulosclerosis at week 4 after subtotal
nephrectomy, and many glomeruli showed strong positive staining
for PDGF-B at this stage. We and others have shown that TRX at
this dose does not substantially attenuate the development of
glomerulosclerosis at later time points [3, 5]. Thus, we speculate,
based on the previous characterization of long-term outcome with
TRX at this dose, that even the non-sclerotic glomeruli with
strong positive staining for PDGF-B in TRX treated rats at week
4 will ultimately progress to glomerubosclerosis. The results
further indicate that PDGF is a specific determinant of the
heterogeneity of the advancement of glomerulosclerosis among
individual glomeruli.
This heterogeneous PDGF expression may be specifically
linked to heterogeneity of the renin-angiotensin system activity.
The renin-angiotensin system is not uniformly activated through-
out the kidney. Local levels of its components are variable [44],
and the angiotensin II receptor localizes specifically to those
glomerular areas often involved in the early phases of sclerosis,
that is, hilar and mesangial areas [45]. Recent studies of cardio-
vascular disease have also shown key interactions between Ang II
and PDGF: Thus, exogenous Ang II infusion, in doses which
caused moderate hypertension, induced marked vascular, gbomer-
ular, and tubulointerstitial injury in association with up-regulation
of PDGF-B chain mRNA [461. Of interest, increased protein and
proteoglycan synthesis in the aorta in response to exogenous Ang
II preceded increased systemic blood pressure [471. Further, the
mitogenic effect of Ang II on vascular smooth muscle cells under
mechanical strain can be largely eliminated by neutralizing anti-
body to PDGF-AB protein [48]. In a model of vessel wall injury,
PDGF expression was enhanced locally, with different PDGF
gene expression pattern in the neointimal vascular smooth muscle
cells compared to underlying vascular smooth muscle cells [49].
Neointimal cells showed marked proliferation in response to Ang
II, in contrast to adjacent differentiated vascular smooth muscle
cells which only underwent hypertrophy [50]. Local conditions
also modify the response to growth factors. Mesangial cells in
routine culture readily proliferate in response to PDGF-B and
express PDGF-/3 receptors, whereas culture under three dimen-
sional conditions within a matrix network renders mesangial cells
of a distinctly different phenotype [51]. The PDGF-/3 receptor is
down-regulated and the cells do not proliferate in response to
PDGF. Interestingly, these cells do show substantial amounts of
induced collagen IV and V production. Enhanced matrix accu-
mulation in even a segment of the glomerulus in vivo could
similarly lead to down-regulation of PDGF expression in later
stages of sclerosis, when other growth factors are activated, with
resultant loss of response to maneuvers which target PDGF. The
possibility exists that the state of differentiation and receptor
modulation may be markedly altered locally at a site of injury,
with resultant augmented local response to specific growth fac-
tors.
Recent advances allow quantitative determination of specific
mRNAs from even a single gbomerulus by in situ reverse tran-
scriptase PCR. Peten et al [52] have used this methodology on
human tissue, finding a positive correlation of increased expres-
sion of collagen type IV (a2) mRNA with the existence of
gbomerulosclerosis. PDGF-B expression may be an even earlier
marker of incipient glomerulosclerosis. Thus, the level of gbomer-
ular PDGF-B mRNA may allow us to predict the responsiveness
of the kidney to treatment, bypassing the long-term follow-up or
multiple biopsies currently required to assess efficacy of interven-
tion. At this early stage of sclerosis, ACEI or AuRA are highly
effective in ameliorating or even reversing progression [1]. How-
ever, future studies are required to elucidate the specific mecha-
nisms involved in Ang II modulation of PDGF expression.
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